{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:50:43Z","timestamp":1793051443250,"version":"4.5.0"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1097\/md.0000000000006290","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T15:21:04Z","timestamp":1488900064000},"page":"e6290","source":"Crossref","is-referenced-by-count":21,"title":["Real role of \u03b2-blockers in regression of left ventricular mass in hypertension patients"],"prefix":"10.1097","volume":"96","author":[{"given":"FuWei","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BinLiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingzhou","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anli","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yili","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-62-20210226","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1097\/HJH.0b013e328330b845","article-title":"Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values","volume":"27","author":"Bombelli","year":"2009","journal-title":"J Hypertens"},{"key":"R2-62-20210226","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08037050701461084","article-title":"2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"16","author":"Mansia","year":"2007","journal-title":"Blood Pressur"},{"key":"R3-62-20210226","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1001\/jama.292.19.2343","article-title":"Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events","volume":"292","author":"Okin","year":"2004","journal-title":"JAMA"},{"key":"R4-62-20210226","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/HJH.0b013e328338c20e","article-title":"Relationship of left atrial enlargement to persistence or development of ECG left ventricular hypertrophy in hypertensive patients: implications for the development of new atrial fibrillation","volume":"28","author":"Okin","year":"2010","journal-title":"J Hypertens"},{"key":"R5-62-20210226","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/eurheartj\/ehm605","article-title":"Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular Health Study","volume":"29","author":"de Simone","year":"2008","journal-title":"Eur Heart J"},{"key":"R6-62-20210226","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/HJH.0b013e3282f35c67","article-title":"Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial","volume":"26","author":"Schmieder","year":"2008","journal-title":"J Hypertens"},{"key":"R7-62-20210226","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","article-title":"Regression of left ventricular mass by antihypertensive treatment a meta-analysis of randomized comparative studies","volume":"54","author":"Fagard","year":"2009","journal-title":"Hypertension"},{"key":"R8-62-20210226","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am J Med"},{"key":"R9-62-20210226","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jama.1996.03530430051039","article-title":"Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies","volume":"275","author":"Schmieder","year":"1996","journal-title":"JAMA"},{"key":"R10-62-20210226","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jash.2011.06.001","article-title":"ACCF\/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension","volume":"5","author":"Aronow","year":"2011","journal-title":"J Am Soc Hypertens"},{"key":"R11-62-20210226","first-page":"1359","article-title":"Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial","volume":"15","author":"Ca Lar","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R12-62-20210226","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"key":"R13-62-20210226","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"R14-62-20210226","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0272989X12458724","article-title":"Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials","volume":"33","author":"Dias","year":"2013","journal-title":"Medical Decis Making"},{"key":"R15-62-20210226","first-page":"E705","article-title":"Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis","volume":"16","author":"Rudroju","year":"2013","journal-title":"Pain Physician"},{"key":"R16-62-20210226","doi-asserted-by":"crossref","first-page":"e3302","DOI":"10.1097\/MD.0000000000003302","article-title":"Comparative effectiveness of blood pressure-lowering drugs in patients who have already suffered from stroke","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine"},{"key":"R17-62-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","article-title":"Bayesian methods for evidence synthesis in cost-effectiveness analysis","volume":"24","author":"Ades","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"R18-62-20210226","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R19-62-20210226","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/HYPERTENSIONAHA.113.02382","article-title":"Adrenal signaling in heart failure: something more than a distant ship's smoke on the horizon","volume":"63","author":"Santulli","year":"2014","journal-title":"Hypertension"},{"key":"R20-62-20210226","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1161\/HYPERTENSIONAHA.110.155960","article-title":"Intracardiac injection of AdGRK5-NT reduces left ventricular hypertrophy by inhibiting NF-B-dependent hypertrophic gene expression","volume":"56","author":"Sorriento","year":"2010","journal-title":"Hypertension"},{"key":"R21-62-20210226","doi-asserted-by":"crossref","first-page":"17818","DOI":"10.1073\/pnas.0804446105","article-title":"The G-protein-coupled receptor kinase 5 inhibits NFkappaB transcriptional activity by inducing nuclear accumulation of IkappaB alpha","volume":"105","author":"Sorriento","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R23-62-20210226","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.4065\/77.11.1199","article-title":"Beta-blockers in chronic heart failure: considerations for selecting an agent","volume":"77","author":"Kukin","year":"2002","journal-title":"Mayo Clinic Proc"},{"key":"R24-62-20210226","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1006\/jmcc.2000.1123","article-title":"Myocardial-directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice","volume":"32","author":"Bisognano","year":"2000","journal-title":"J Mol Cell Cardiol"},{"key":"R25-62-20210226","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1073\/pnas.96.12.7059","article-title":"Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice","volume":"96","author":"Engelhardt","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-62-20210226","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.8160017","article-title":"Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor","volume":"264","author":"Milano","year":"1994","journal-title":"Science (NY"},{"key":"R27-62-20210226","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1161\/01.CIR.101.14.1707","article-title":"Early and delayed consequences of beta(2)-adrenergic receptor overexpression in mouse hearts: critical role for expression level","volume":"101","author":"Liggett","year":"2000","journal-title":"Circulation"},{"key":"R28-62-20210226","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/HJH.0b013e328337598c","article-title":"Cardiovascular protective effects of nebivolol in Zucker diabetic fatty rats","volume":"28","author":"Toblli","year":"2010","journal-title":"J Hypertens"},{"key":"R29-62-20210226","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000099201","article-title":"Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol","volume":"19","author":"Wolf","year":"2007","journal-title":"Cell Physiol Biochem"},{"key":"R30-62-20210226","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1089-8603(02)00113-1","article-title":"Nebivolol inhibits vascular smooth muscle cell proliferation by mechanisms involving nitric oxide but not cyclic GMP","volume":"7","author":"Ignarro","year":"2002","journal-title":"Nitric Oxide"},{"key":"R31-62-20210226","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/00005344-200006000-00003","article-title":"Nebivolol inhibits human aortic smooth muscle cell growth: effects on cell cycle regulatory proteins","volume":"35","author":"Andre","year":"2000","journal-title":"J Cardiovasc Pharmacol"},{"key":"R32-62-20210226","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1097\/HJH.0b013e3282efeecb","article-title":"Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction","volume":"25","author":"Pires","year":"2007","journal-title":"J Hypertens"},{"key":"R33-62-20210226","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1161\/HYPERTENSIONAHA.107.094458","article-title":"Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation","volume":"50","author":"Maffei","year":"2007","journal-title":"Hypertension"},{"key":"R34-62-20210226","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1097\/HJH.0b013e32832ea925","article-title":"Nebivolol induces parallel improvement of left ventricular filling pressure and coronary flow reserve in uncomplicated arterial hypertension","volume":"27","author":"Galderisi","year":"2009","journal-title":"J Hypertens"},{"key":"R35-62-20210226","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0008-6363(00)00253-4","article-title":"Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells","volume":"49","author":"Brehm","year":"2001","journal-title":"Cardiovasc Res"},{"key":"R36-62-20210226","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/ndt\/gfi237","article-title":"Hypertensive myocardial fibrosis","volume":"21","author":"Cuspidi","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R37-62-20210226","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0894-7317(97)70028-2","article-title":"Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization","volume":"10","author":"Ciulla","year":"1997","journal-title":"J Am Soc Echocardiogr"},{"key":"R38-62-20210226","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/HJH.0b013e3282f283c9","article-title":"A comparison of atenolol and nebivolol in isolated systolic hypertension","volume":"26","author":"Dhakam","year":"2008","journal-title":"J Hypertens"},{"key":"R39-62-20210226","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1161\/01.HYP.0000137983.45556.6e","article-title":"Nebivolol increases arterial distensibility in vivo","volume":"44","author":"McEniery","year":"2004","journal-title":"Hypertension"},{"key":"R40-62-20210226","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/HJH.0b013e328333d228","article-title":"Relations of central and brachial blood pressure to left ventricular hypertrophy and geometry: the Strong Heart Study","volume":"28","author":"Roman","year":"2010","journal-title":"J Hypertens"},{"key":"R41-62-20210226","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/00129784-200808010-00005","article-title":"Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis","volume":"8","author":"Van Bortel","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"key":"R42-62-20210226","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/ajh.2009.253","article-title":"Additive interaction of metabolic syndrome and chronic kidney disease on cardiac hypertrophy, and risk of cardiovascular disease in hypertension","volume":"23","author":"Iwashima","year":"2010","journal-title":"Am J Hypertens"},{"key":"R43-62-20210226","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1291\/hypres.25.167","article-title":"Relationship between home blood pressure and longitudinal changes in target organ damage in treated hypertensive patients","volume":"25","author":"Tsunoda","year":"2002","journal-title":"Hypertens Res"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000006290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:45:10Z","timestamp":1620960310000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201703100-00062"}},"subtitle":["Bayesian network meta-analysis"],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000006290","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]}}}